A Trial of NOV-205 in Hepatitis C Patients Who Failed Standard Therapy

A Phase 2 Trial of NOV-205 in Chronic Viral Hepatitis C Patients (Genotype 1) Who Have Failed Treatment With Pegylated Interferon Plus Ribavirin

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01058512

Acronym

NOV-205

Enrollment

Registered

2010-01-28

Start date

2010-03-31

Completion date

2010-12-31

Last updated

2022-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C

Keywords

hepatitis C, chronic HCV, viral HCV, genotype 1, failed treatment with pegylated interferon plus ribavirin

Brief summary

The purpose of this research study is to find out the effect of the investigational drug NOV-205 on the level of hepatitis C virus in the blood and whether NOV-205 is well-tolerated at different doses when taken by subjects with hepatitis C.

Interventions

DRUGNOV-205

There will be 4 treatment Groups with 10 patients in each group: * Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days * Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days * Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days * Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* A serum HCV RNA level of \>100,000 IU/ml using a quantitative, branched-chain-DNA (bDNA)-based assay (lower limit of quantitation = \ 650 IU/ml) or other equally sensitive quantitative methods. * Infection with genotype 1 HCV * Documented failure to respond to treatment (defined as a patient who did not achieve an early viral response (EVR) (≥2 log reduction in serum HCV RNA or undetectable HCV RNA after 12 weeks of treatment) OR is serum HCV RNA positive after 24 weeks of treatment with pegylated interferon plus ribavirin for hepatitis C * Adequate laboratory parameters * Women of childbearing potential willing to use two acceptable methods of birth control during trial participation or are sterile or post-menopausal (defined as not having a menstrual cycle for greater than two years) * Sexually active male subjects are practicing acceptable methods of contraception during trial participation * Have the ability to understand the requirements of the trial, have provided written informed consent, and agree to abide by the trial restrictions and to return for the required assessments * The subject must be able to self administer daily subcutaneous injections or their caregiver must be able to administer daily subcutaneous injections

Exclusion criteria

* Clinical, laboratory, or histological evidence of liver cirrhosis * Evidence of hepatic decompensation (presence of or a history of ascites, hepatic encephalopathy, variceal bleeding, or hepatocellular carcinoma) * Co-infection with human immunodeficiency virus (HIV) or active hepatitis B virus (HBV) (as determined by presence of hepatitis B surface antigen (HBsAg) * Have received pegylated interferon and/or ribavirin within the 60 days prior to enrollment * Any known preexisting medical condition that could interfere with the subject's participation in and completion of the protocol * Pregnant female or nursing mother

Design outcomes

Primary

Measure	Time frame
To evaluate changes in viral load	16 months
To evaluate changes in serum ALT and AST levels	16 months
To evaluate the durability of any changes in viral load and serum ALT and AST	16 months
To establish the safety profile of NOV-205	16 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026